# LIMBER (NCT04279847)

> Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04279847
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Myelofibrosis; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome; Myeloproliferative Neoplasm; Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis); ET (Essential Thrombocythemia)
- Interventions: INCB057643; Ruxolitinib
- Enrollment: 140
- Primary outcome: Number of treatment-emergent adverse events

## Indexed commentary on LIMBER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=limber-nct04279847